| Contract Development and Manufacturing Organization (CDMO) | Pharmaceutical contract manufacturing including oral solids, liquids, injectables, and specialized dosage forms. | EU-GMP certification, geographic manufacturing scale, diverse dosage form capability, and strong regulatory compliance. | Pharmaceutical manufacturers globally requiring high-quality pharma manufacturing services. | Specialized injectables and hormonal products with high technology requirements. | 3207 | 77 | Sales of manufacturing services through contracts mainly to pharmaceutical companies (B2B). | Contract-based revenue, long-term agreements, volume and service-based billing. | Increasing pharma outsourcing trends, capacity expansion, regulatory certifications boosting global supplies. | |
| Active Pharmaceutical Ingredients (API) | Development and manufacture of APIs focusing on anti-infectives, respiratory, diabetes, and specialty chemicals. | Technical expertise in complex chemical synthesis and regulatory certifications. | Pharmaceutical companies (B2B) using APIs for formulation development. | Specialty APIs in β-lactams and penems segments. | 219 | 5 | Sales of API products domestically and internationally to pharma manufacturers. | Product sales, volume discounts, and supply agreements. | New molecule development and portfolio rationalization, global demand for anti-infective APIs. | |
| Domestic Branded Formulations | Manufacture and sale of branded pharmaceutical products for the Indian market. | Established brand presence and focused distribution networks. | Indian consumers and healthcare providers. | Branded, specialty medicines in dermatology and general therapeutics. | 433 | 10 | Sales through retail and institutional channels (B2C and B2B). | Direct sales and distribution partnerships with competitive pricing. | Growing domestic healthcare demand and expansion of product portfolio. | |
| International Branded Formulations | Export sale of branded pharmaceutical formulations to emerging and regulated markets. | Global certifications and growing international footprint. | International pharmaceutical distributors and healthcare providers. | Branded specialty products compliant with global standards. | 143 | 3 | Sales through export distribution and partnerships (B2B and B2C). | Export sales with regulatory-compliant products and market approvals. | Recovery in international demand, new market entries, regulatory approvals. | |
| Trade Generics | Wholesale generic formulations for domestic and export markets. | Strong supply chain and generic product availability. | Generic drug distributors and pharmacy chains (B2B). | Limited due to competitive pricing pressures. | 115 | 3 | Sales volume-driven revenues from generic product distribution. | Competitive pricing with focus on volume sales. | Portfolio rationalization and cost management efforts underway to improve performance. | |
